muramylnac-ala-isogln-lys-tripeptide has been researched along with EHS Tumor in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jarowenko, DG; Pellis, NR; Sigler, SC | 1 |
1 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and EHS Tumor
Article | Year |
---|---|
Muramyl tripeptide: an effective immunotherapy in the surgical setting for pediatric abdominal neoplasms.
Topics: Abdominal Neoplasms; Acetylmuramyl-Alanyl-Isoglutamine; Animals; Female; Fibrosarcoma; Immunity, Cellular; Immunotherapy; Liposomes; Macrophage Activation; Mice; Mice, Inbred C3H; Micelles; Neoplasm Seeding; Peritoneal Neoplasms; Sarcoma, Experimental; Time Factors | 1987 |